Unknown PHASE2 INTERVENTIONAL 2-arm NCT03609489

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Apatinib Combined Capecitabine Versus Capecitabine Alone for Adjuvant Therapy in Patients After Biliary Carcinoma Surgery: a Prospective Randomized Controlled Study

Sponsor: First Affiliated Hospital of Guangxi Medical University

Conditions Biliary Carcinoma

Interventions Apatinib Capecitabine

Updated 6 times since 2018 Last updated: Aug 7, 2018 Started: Sep 10, 2018 Primary completion: Jun 10, 2021 Completion: Dec 25, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Biliary Carcinoma and is currently ongoing. First Affiliated Hospital of Guangxi Medical University leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE2
Sep 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Aug 2018 — Sep 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Guangxi Medical University

Data source: First Affiliated Hospital of Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China